Chen JJ, Swope DM, « Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease », J Clin Pharmacol, vol. 45, no 8, , p. 878–94 (PMID16027398, DOI10.1177/0091270005277935, lire en ligne [archive du ], consulté le )
Orit Bar Am, Tamar Amit et Moussa B. H. Youdim, « Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline », Neuroscience Letters, vol. 355, no 3, , p. 169–172 (ISSN0304-3940, PMID14732458, DOI10.1016/j.neulet.2003.10.067, S2CID20471004)
Chen JJ, Swope DM, « Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease », J Clin Pharmacol, vol. 45, no 8, , p. 878–94 (PMID16027398, DOI10.1177/0091270005277935, lire en ligne [archive du ], consulté le )
Binda C, Hubálek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A, « Binding of Rasagiline-related Inhibitors to Human Monoamine Oxidases: A Kinetic and Crystallographic Analysis », Journal of Medicinal Chemistry, vol. 48, no 26, , p. 8148–54 (PMID16366596, PMCID2519603, DOI10.1021/jm0506266)
(en) Joaquim J. Ferreira, Dulce Neutel, Tiago Mestre et Miguel Coelho, « Skin cancer and Parkinson's disease », Movement Disorders, vol. 25, no 2, , p. 139–148 (ISSN1531-8257, DOI10.1002/mds.22855, lire en ligne, consulté le )
(en) Olivier Rascol, Robert A. Hauser, Fabrizio Stocchi et Cheryl J. Fitzer‐Attas, « Long-term effects of rasagiline and the natural history of treated Parkinson's disease », Movement Disorders, vol. 31, no 10, , p. 1489–1496 (ISSN1531-8257, DOI10.1002/mds.26724, lire en ligne, consulté le )
Pierre Arsenault et Valérie Chiasson-Roussel, « La maladie de Parkinson-II : la place de la rasagiline (Azilect) », Le Médecin du Québec, vol. 43, no 12, , p. 87-9. (lire en ligne [PDF])
Orit Bar Am, Tamar Amit et Moussa B. H. Youdim, « Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline », Neuroscience Letters, vol. 355, no 3, , p. 169–172 (ISSN0304-3940, PMID14732458, DOI10.1016/j.neulet.2003.10.067, S2CID20471004)
(en) Joaquim J. Ferreira, Dulce Neutel, Tiago Mestre et Miguel Coelho, « Skin cancer and Parkinson's disease », Movement Disorders, vol. 25, no 2, , p. 139–148 (ISSN1531-8257, DOI10.1002/mds.22855, lire en ligne, consulté le )
(en) Olivier Rascol, Robert A. Hauser, Fabrizio Stocchi et Cheryl J. Fitzer‐Attas, « Long-term effects of rasagiline and the natural history of treated Parkinson's disease », Movement Disorders, vol. 31, no 10, , p. 1489–1496 (ISSN1531-8257, DOI10.1002/mds.26724, lire en ligne, consulté le )
nih.gov
ncbi.nlm.nih.gov
(en) Andreas Kupsch, « Rasagiline. Teva Pharmaceutical », Curr Opin Investig Drugs, vol. 3, no 5, , p. 794-7. (PMID12090555)modifier
G Engberg, T Elebring et H Nissbrandt, « Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons », The Journal of Pharmacology and Experimental Therapeutics, vol. 259, no 2, , p. 841–7 (PMID1658311)
Orit Bar Am, Tamar Amit et Moussa B. H. Youdim, « Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline », Neuroscience Letters, vol. 355, no 3, , p. 169–172 (ISSN0304-3940, PMID14732458, DOI10.1016/j.neulet.2003.10.067, S2CID20471004)
Chen JJ, Swope DM, « Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease », J Clin Pharmacol, vol. 45, no 8, , p. 878–94 (PMID16027398, DOI10.1177/0091270005277935, lire en ligne [archive du ], consulté le )
Binda C, Hubálek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A, « Binding of Rasagiline-related Inhibitors to Human Monoamine Oxidases: A Kinetic and Crystallographic Analysis », Journal of Medicinal Chemistry, vol. 48, no 26, , p. 8148–54 (PMID16366596, PMCID2519603, DOI10.1021/jm0506266)
Lecht S, Haroutiunian S, Hoffman A, Lazarovici P, « Rasagiline – a novel MAO B inhibitor in Parkinson's disease therapy », Ther Clin Risk Manag, vol. 3, no 3, , p. 467–74 (PMID18488080, PMCID2386362)
Chen JJ, Swope DM, « Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease », J Clin Pharmacol, vol. 45, no 8, , p. 878–94 (PMID16027398, DOI10.1177/0091270005277935, lire en ligne [archive du ], consulté le )
Orit Bar Am, Tamar Amit et Moussa B. H. Youdim, « Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline », Neuroscience Letters, vol. 355, no 3, , p. 169–172 (ISSN0304-3940, PMID14732458, DOI10.1016/j.neulet.2003.10.067, S2CID20471004)
wikipedia.org
fr.wikipedia.org
(en) Andreas Kupsch, « Rasagiline. Teva Pharmaceutical », Curr Opin Investig Drugs, vol. 3, no 5, , p. 794-7. (PMID12090555)modifier
wiley.com
movementdisorders.onlinelibrary.wiley.com
(en) Joaquim J. Ferreira, Dulce Neutel, Tiago Mestre et Miguel Coelho, « Skin cancer and Parkinson's disease », Movement Disorders, vol. 25, no 2, , p. 139–148 (ISSN1531-8257, DOI10.1002/mds.22855, lire en ligne, consulté le )
onlinelibrary.wiley.com
(en) Olivier Rascol, Robert A. Hauser, Fabrizio Stocchi et Cheryl J. Fitzer‐Attas, « Long-term effects of rasagiline and the natural history of treated Parkinson's disease », Movement Disorders, vol. 31, no 10, , p. 1489–1496 (ISSN1531-8257, DOI10.1002/mds.26724, lire en ligne, consulté le )
